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Abstract
A major outbreak of West Nile virus (WNV) infections took
place in 2010 in Greece. Apart from the neuroinvasive cases,
many additional cases without involvement of the nervous
system were observed, characterized by high fever, myalgia,
rash, leukopenia, and long-lasting recovery. West Nile non-
neuroinvasive disease is a distinct clinical syndrome, and is not
always mild.
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West Nile virus (WNV) infections are usually asymptomatic
or mild, and are referred to as West Nile fever [1,2].
Approximately 20% of the infections present with fever,
often accompanied by rash, and <1% present as neuro-
invasive disease (West Nile neuroinvasive disease (WNND))
(mainly encephalitis or meningoencephalitis). Although recov-
ery from mild infections is complete, involvement of the
central nervous system is associated with a mortality rate of
up to 10% and long-term morbidity [3]. CCR5 deﬁciency
increases the risk of symptomatic infection, and depressed
immunity, age and underlying diseases are correlated with
greater risk of WNND [4].
During July to October 2010, a large-scale WNV outbreak
occurred in Greece [5]. Over a 14-week period, 197
WNND cases were reported [6]. Lineage 2 WNV was
detected in individual donation-nucleic acid testing-positive
blood donors, and in mosquitoes [7,8] (A. Papa, C. Politis, A.
Tsoukala, A. Eglezou, V. Bakaloudi, M. Hatzitaki, K. Tsergouli,
submitted). The highest WNND incidence was seen in Pella
and Imathia prefectures in Central Macedonia, northern
Greece (28.26 and 27.06 per 100 000 population, respec-
tively).
Apart from the WNND cases, 65 West Nile non-neuroin-
vasive disease (WNNND) cases were reported. This repre-
sents only a partial number, as the number of patients
presenting to the hospitals and health centres in the affected
areas, with fever, headache, myalgia, arthralgia, and rash, was
extremely high. The aim of the present study was to
describe the clinical manifestations of the WNNND cases
during the outbreak of WNV infections in 2010 in Greece.
The study took place in Giannitsa, the largest city of Pella
prefecture (the one with the highest incidence). During July
to October 2010, 29 patients (15 male) with encephalitis or
encephalomyelitis were hospitalized in Giannitsa General
Hospital. Their median age was 74 years (range, 25–87
years). Ten patients died. During the same period, an
unexpectedly high number of younger patients presented to
the hospital with sudden onset of fever, frontal and occipital
headache, severe dizziness, gait instability, malaise, myalgia,
muscular weakness, back pain, and arthralgia. Many patients
presented nausea, vomiting, anorexia, and diarrhoea, and
60–70% presented roseoral or maculopapular rash without
pruritus, which occurred in the middle or late course of the
disease, mainly on the trunk, neck, and upper limbs, lasted
for about 4–5 days, and disappeared with the decline of
fever. The fever was as high as 40C, and lasted for a few
days to 2–3 weeks. The persistence of high fever, the intense
malaise and anorexia led to a large number of patients expe-
riencing weight loss of up to 10–15 kg. The main laboratory
ﬁnding was leukopenia, lasting for 6–10 days, and the initial
ﬁnding was mononucleosis, which decreased with the onset
of leukopenia. Convalescence lasted for several days, or even
months, and during this time patients experienced severe
fatigue and malaise.
Serum samples of the ﬁrst patients drawn on the ﬁrst visit
to the hospital were negative for WNV antibodies, which
were detectable in the follow-up samples; it was soon
realized that antibodies present later in WNNND than in
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WNND [9]. It was estimated that, during the 4-month per-
iod, 300 patients with suspected WNNND visited the hospi-
tal. Four were hospitalized. Symptomatic treatment was
administered, and psychological support was often needed,
because of the fear of imminent death.
In order to determine whether WNV was the cause of
the disease, patients were informed about the study and
agreed to be tested for the presence of WNV IgM and IgG
antibodies. One hundred patients responded to the call
(response rate, 33.3%); a sample was obtained 2–4 months
after onset of the illness. Detection of WNV IgM and IgG
antibodies was achieved with ELISA (WNV IgM capture
DxSelect and WNV IgG DxSelect; Focus Diagnostics,
Cypress, CA, USA).
Ninety-ﬁve (95%) patients were WNV antibody-positive:
82 for both IgM and IgG, and seven for IgG, with IgM titres
close to the cut-off value (these patients were tested
4 months after onset of the illness). Among the 95 patients,
35 (36.84%) were male and 60 (63.16%) were female, aged
16–80 years (mean, 51.7 years; standard deviation (SD),
17.1). The main clinical signs and symptoms are shown in
Table 1. Fever (mean, 38.5C; SD, 0.77), fatigue, headache
and arthralgia/myalgia were the most common symptoms.
Sixty-one patients presented exanthema, shortly after the
peak of fever. A striking ﬁnding was the severe leukopenia,
observed in the vast majority of patients (51/69 (73.91%)
who were tested on the initial visit to the hospital). The
white blood cell count ranged from 1000 to 12 000 cells/lL
(mean, 4028; SD, 1849), with 40–60% neutrophils. C-reactive
protein was in the normal range. Nine patients had fever for
more than 1 week (one for 22 days).
Symptoms resolved after 3–10 days (mean, 5 days); how-
ever, 13 (13.7%) patients continued to have symptoms for a
longer time (1–2 months). A slight tremor was observed in
the patients with the more severe form of the disease. Tre-
mor and transient parkinsonism have been reported in previ-
ous studies, and it was suggested that involvement of the
basal ganglia may be characteristic for WNV infection [10,11].
Although West Nile fever is considered to be a mild dis-
ease, many of the patients suffered greatly. The following are
some of their statements: ‘I thought I would die’; ‘I had
never been so heavily ill before’; ‘I was unable to make a sin-
gle step’; and ‘I felt like I was being hit with a hammer’.
The fact that no fatalities were observed among these
patients, together with the presence of rash in 64.21% of
cases, as compared with 10.34% (3/29) in WNND patients,
among whom the fatality rate was 34.5%, suggests that rash
might have a favourable effect regarding severe disease and
mortality in WNV disease. Rash as a marker of good progno-
sis has been highlighted previously [12]. The involvement of
diverse target host cells and the release of various cytokines
and cytotoxic factors, resulting in differences in immune
response, might explain the variations in clinical signs and
symptoms, and the severity and outcome of the disease.
Patients were previously in good health, and only few of
them had an underlying disease (Table 1). Resurgence of pso-
riasis was seen in one patient, suggesting that WNV further
suppresses immune deﬁciency.
In conclusion, WNNND, a common type of WNV infec-
tion, constitutes a distinct clinical syndrome that should not
always be considered a ‘mild disease’.
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Respiratory symptoms 2 (2.11)
Underlying diseases
Hypertension 7 (7.37)
Diabetes mellitus 6 (6.32)
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